Dexamethasone Sodium Phospha · #13 of 35 active shortages by FDA posting duration
Brand: DEXAMETHASONE SODIUM PHOSPHATE
FDA lists Dexamethasone Sodium Phospha as Active Shortage (Somerset Therapeutics, LLC).
Availability on file: Available
Dexamethasone Sodium Phosphate Injection: Active Shortage
Available 16 shortage presentations are tracked for this drug. Contact your pharmacist if you are affected.
Shortage Details
- Generic Name
- Dexamethasone Sodium Phosphate Injection
- Manufacturer
- Somerset Therapeutics, LLC
- Dosage Form
- Injection
- Presentation
- Dexamethasone Sodium Phosphate Preservative Free, Injection, 10 mg/1 mL (NDC 70069-021-25)
- Package NDC
- 70069-021-25
Status & Timeline
- Status
- Active Shortage
- Availability
- Available
- First Reported
- Feb 8, 2019
- Last Updated
- Aug 19, 2025
- Therapeutic Category
- Dermatology, Endocrinology/Metabolism, Gastroenterology, Hematology, Neurology, Oncology, Ophthalmology, Other, Pulmonary/Allergy, Rheumatology
Row fields from the FDA Drug Shortages database via openFDA.
Full Drug Profile
dexamethasone
Side effects, interactions, warnings & more
Nearby, Other Dexamethasone Shortage Records
Dexamethasone Sodium Phosphate Injection
Mylan Institutional, a Viatris Company
Injection
Dexamethasone Sodium Phosphate Injection
Mylan Institutional, a Viatris Company
Injection
Dexamethasone Sodium Phosphate Injection
Mylan Institutional, a Viatris Company
Injection
Dexamethasone Sodium Phosphate Injection
Eugia US LLC
Injection
Dexamethasone Sodium Phosphate Injection
Mylan Institutional, a Viatris Company
Injection
Dexamethasone Sodium Phosphate Injection
Fresenius Kabi USA, LLC
Injection